טוען...
Oncolytic Viruses: Priming Time for Cancer Immunotherapy
New immuno-oncology therapies are improving cancer treatments beyond the former standard of care, as evidenced by the recent and continuing clinical approvals for immunotherapies in a broad range of indications. However, a majority of patients (particularly those with immunologically cold tumors) st...
שמור ב:
| הוצא לאור ב: | BioDrugs |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Springer International Publishing
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6790338/ https://ncbi.nlm.nih.gov/pubmed/31321623 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40259-019-00367-0 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|